Parabilis Medicines (PBLS)
Develops Helicon peptides for hard-to-reach intracellular protein targets.
Something off on this page? Send us feedback.
Develops Helicon peptides and drug candidates that target hard-to-reach intracellular protein surfaces, led by zolucatetide for Wnt/beta-catenin-driven disease. The clinical-stage business is financed through equity capital and collaboration payments, with no approved products.
Develops stabilized alpha-helical peptides, called Helicons, designed to enter cells and bind protein surfaces beyond the reach of conventional small molecules and biologics. The platform combines proprietary peptide chemistry and screening with automated synthesis, physics-based computation, artificial intelligence, and translational and clinical data. It supports direct protein-interaction inhibitors, bifunctional degraders, antibody conjugates, and radioligand payload delivery.
Advances zolucatetide, a direct beta-catenin:TCF inhibitor, in an ongoing trial centered on desmoid tumors and expansion settings across Wnt/beta-catenin-driven disease, while developing prostate-cancer degraders and earlier discovery programs. Research partnerships include Regeneron on certain Helicon programs and ARTBIO on lead-212 radioligand therapies. Operations are based in Cambridge, with clinical activity across U.S. and international sites; clinical and future commercial supply is outsourced.
Company facts
Unavailable right now.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $1.12B · Total debt $47.5M · Total assets $1.18B · Shareholders' equity $1.05B
- Revenue
- $148.0K
- Operating income
- −$50.9M
- Net income
- −$52.5M
No dividends on record.
123.53M company shares as of Sep 3, 2026 · holders as of their latest filing
This company has 2 share classes; every stake here is a share of the whole company.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
ARCH Venture Fund XII, L.P.Institution | 5.19% | 6.41M | 13Gfiled Aug 14, 2026 ↗ |
RA Capital Management, L.P.Institution | —23.80% of class, as filed | — | 13Dfiled Jun 18, 2026 ↗ |
13D/13G — an ownership statement filed at 5% or more
Insider tradesForm 4
No open-market trades in the last 12 months.
- Immunome
Late-stage varegacestat rivals zolucatetide in desmoid tumors.
- Biodexa Pharmaceuticals (ADR)
Phase 3 eRapa targets FAP polyp burden.
- Recursion Pharmaceuticals
Phase 2 REC-4881 targets FAP polyp burden.
- Tempest Therapeutics
Planned Phase 2 TPST-1495 adds a lower-weight FAP threat.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Parabilis Medicines | $40.04 | +1.44% | $4.68B | — | — | 31,590.6 | — |
| Immunome | $27.32 | +0.94% | $2.61B | — | — | — | — |
| Biodexa Pharmaceuticals (ADR) | $0.7715 | −1.71% | $585.6K | — | — | — | — |
| Recursion Pharmaceuticals | $3.37 | −0.19% | $1.77B | — | — | 32.3 | −61.8% |
| Tempest Therapeutics | $1.10 | 0.00% | $17.6M | — | — | — | — |
| Median | — | — | 32.3 | −61.8% |